首页> 外文期刊>JAMA: the Journal of the American Medical Association >Should glucocorticoid-induced hyperglycemia be treated in patients with septic shock?
【24h】

Should glucocorticoid-induced hyperglycemia be treated in patients with septic shock?

机译:败血性休克患者应治疗糖皮质激素引起的高血糖吗?

获取原文
获取原文并翻译 | 示例
       

摘要

CRITICAL ILLNESS, IN PARTICULAR SEVERE SEPSIS, induces insulin resistance and hyperglycemia. Corticosteroids are often used for reversal of fluid- and vasopressor-resistant septic shock. Such an adjuvant treatment aggravates illness-induced hyperglycemia, even in a low-dose steroid regimen. For glucocorticoid-induced hyperglycemia in noncritically ill patients, there is general agreement on treatment, because prolonged hyperglycemia causes cardiovascular and infectious complications. Whether patients in septic shock in the intensive care unit (ICU) with glucocorticoid-induced aggravation of "diabetes of injury" should be treated is controversial. This debate is embedded in the overall controversy about whether to treat critically ill patients with hyperglycemia with insulin, and if so, to what blood glucose level.
机译:严重的疾病,特别是严重的脓毒症,会引起胰岛素抵抗和高血糖症。皮质类固醇常被用于逆转耐液体和升压药性脓毒性休克。即使在低剂量类固醇治疗方案中,这种辅助治疗也会加重疾病引起的高血糖症。对于非危重症患者的糖皮质激素诱发的高血糖症,治疗方面存在普遍共识,因为长时间的高血糖症会引起心血管和感染并发症。在重症监护病房(ICU)中因糖皮质激素引起的“损伤性糖尿病”加重而导致感染性休克的患者是否应该治疗尚存争议。这场辩论存在于关于是否使用胰岛素治疗重症高血糖重症患者,以及是否可以治疗何种血糖水平的总体争议中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号